Team America: World Police

PROOF INC. CELEBRATES 20 YEARS OF VISUALIZATION; ACROSS THE POND, PROOF LONDON TURNS 10

Retrieved on: 
Tuesday, October 4, 2022
Universe, DC Universe, Blacklist, Winter Soldier, No, HBO Max, Suicide Squad, Advertising, Fast & Furious, The Twilight Saga, Frankel, The Lego Movie, Netflix, Industry, Television, Blacklisting, Jurassic World, Multimedia, Amazon, The Little Mermaid, Multiverse, Star Trek Beyond, COVID-19, The Wheel of Time, Animation, Stranger Things, Team America: World Police, Creativity, Man of Steel, Indiana Jones in the Lost Kingdom, Film, F9

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ --This year, Proof Inc. celebrates 20 years of providing visualization to the feature film, television, advertising, and multimedia industries.

Key Points: 
  • LOS ANGELES, Oct. 4, 2022 /PRNewswire/ --This year, Proof Inc. celebrates 20 years of providing visualization to the feature film, television, advertising, and multimedia industries.
  • The U.K. arm, Proof London, founded by Frankel and Pawl Fulker, celebrates its 10th anniversary this year.
  • On the founding of Proof, Frankel said, "It was a bold step into the unknown.
  • We've since covered the globe from Western China to Eastern Europe working with the most prolific creatives in the entertainment industry.

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Science, Health, Research, Â, Chemistry, Department, Medicinal chemistry, Cysteine, Lysine, Proteome, Trubion, Proteomics, Patient, Biology, Science, Therapy, Gilead Sciences, Computational chemistry, Terremoto, Industry, List of life sciences, Time, UCSF, Biotechnology, Toxicity, Third Rock Ventures, The Sun Sessions, Team America: World Police, Protein, HIV, Drug discovery, Cancer, Hepatitis, CEO, Fine chemical, Pharmaceutical industry, Incyte, Tetris

Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.

Key Points: 
  • Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
  • Terremoto is redefining what was once thought of as scientifically impossible with our well-defined platform approach and unrivaled team.
  • Terremoto leverages its covalent drug discovery and development engine to create highly targeted, small molecule medicines for a broad spectrum of severe diseases, including cancer.
  • Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy.